Highline Wealth Partners’s Halozyme HALO Stock Holding History

Highline Wealth Partners’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6	Closed	-$383	–	973
2025 Q1	$383	Buy	+6	New	+$349	﹤0.01%	877

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Highline Wealth Partners's HALO Position: Q2 2025 in Review

Highline Wealth Partners sold out of Halozyme (HALO) in Q2 2025, closing a stake of 6 shares — an estimated $383 sold.

Highline Wealth Partners first reported a position in HALO in Q1 2025 and held it in 1 quarter. The position peaked at $383 in Q1 2025. 551 funds tracked by Wall St. Rank hold HALO as of Q2 2025.

Highline Wealth Partners reported no remaining Halozyme position as of Q2 2025 after selling out during the quarter.
Highline Wealth Partners sold 6 Halozyme shares in Q2 2025, an estimated $383.
Highline Wealth Partners first reported a position in Halozyme in Q1 2025 and held it in 1 quarter.
Highline Wealth Partners's Halozyme position peaked at $383 in Q1 2025.
551 funds tracked by Wall St. Rank held Halozyme as of Q2 2025.

Based on Highline Wealth Partners's 13F filing for Q2 2025, filed 16 Jul 2025.